Breaking News Instant updates and real-time market news.

VKTX

Viking Therapeutics

$10.22

-0.37 (-3.49%)

07:32
04/04/19
04/04
07:32
04/04/19
07:32

Viking Therapeutics to present new data on NAFLD candidate at liver congress

Viking Therapeutics announced that data from the company's 12-week Phase 2 study of VK2809 in patients with non-alcoholic fatty liver disease, or NAFLD, and elevated low-density lipoprotein cholesterol, will be presented at the International Liver Congress 2019 being held April 10-14 in Vienna. The Phase 2 study achieved both its primary and secondary endpoints, and demonstrated an "encouraging" safety and tolerability profile for VK2089, Viking's novel liver-selective thyroid receptor beta agonist. The presentation will include new data from the trial's low-dose 5 mg cohort treatment arm, which demonstrated statistically significant reductions in liver fat content relative to placebo, as well as statistically significant response rates, defined by the proportion of patients experiencing at least a 30% or 50% relative reduction in liver fat, compared with placebo. VK2809 was well tolerated when dosed at 5 mg daily, and no serious adverse events were reported among patients receiving either VK2809 or placebo.

  • 04

    Apr

VKTX Viking Therapeutics
$10.22

-0.37 (-3.49%)

03/29/19
LEER
03/29/19
UPGRADE
LEER
Outperform
Viking Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
03/27/19
HCWC
03/27/19
NO CHANGE
HCWC
Viking data 'impresses again' even at lower dose, says H.C. Wainwright
Viking Therapeutics this morning released the expected data on the 12-week study with the low dose 5 mg arm of VK2809 in patients with non-alcoholic fatty liver disease, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. As discussed during the recent earnings call, the data released today provide evidence that all patients treated with the lowest dose of VK2809 show significant reduction in liver fat content as measured by magnetic-resonance-imaging, protondensity-fat-fraction, says the analyst. In addition, 100% of patients show greater than or equal to 30% reduction in liver fat content at 12 weeks and 70% of patients demonstrated a reduction in liver fat content of more than 50%, according to Pantginis. He says VK2809 "impresses again even at lower dose" and keeps a Buy rating on Viking Therapeutics with a $31 price target.
02/22/19
LEER
02/22/19
INITIATION
Target $10
LEER
Market Perform
Viking Therapeutics initiated with a Market Perform at SVB Leerink
SVB Leerink analyst Pasha Sarraf initiated Viking Therapeutics with a Market Perform rating and $10 price target, telling investors in a research note that Viking is positioning VK2809, a hepatic prodrug, thyroid receptor beta-selective agonist for NASH, as it pursues an IND with the GI division, to start Phase 2b trials this year. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
02/12/19
WBLR
02/12/19
NO CHANGE
WBLR
Viking could emerge as 'prime' buyout target for Gilead, says William Blair
Given Gilead Sciences' (GILD) leadership position in liver diseases and the significant resources that the company has devoted in the development of nonalcoholic steatohepatitis, last night's clinical setback "will likely reinvigorate" the company's willingness to augment its NASH pipeline, William Blair analyst Andy Hsieh tells investors in a research note. The analyst believes Gilead's Phase 3 failure could have a positive read-through to Viking Therapeutics (VKTX), which he notes is one of the only two beta-selective thyroid hormone receptor agonists in clinical testing. Viking's VK2809 demonstrated highly competitive data in reducing liver fat while maintaining a benign tolerability profile, Hsieh contends. Pending positive results from the company's Phase IIb study involving biopsy-confirmed NASH patients, he believes Viking Therapeutics "could emerge as a prime M&A target." The analyst keeps an Outperform rating on the shares. Viking in premarket trading is up 7% to $8.71.

TODAY'S FREE FLY STORIES

DLPH

Delphi Technologies

$22.60

-2 (-8.13%)

13:45
04/25/19
04/25
13:45
04/25/19
13:45
Options
Delphi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

ADTN

Adtran

$17.39

-0.38 (-2.14%)

13:40
04/25/19
04/25
13:40
04/25/19
13:40
Earnings
Adtran VP Roger Shannon sold over $100K in company shares »

Adtran VP Roger Shannon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 08

    May

AVYA

Avaya

$20.22

0.895 (4.63%)

13:34
04/25/19
04/25
13:34
04/25/19
13:34
Periodicals
Mitel offering to combine with Avaya in stock deal worth over $2B, WSJ says »

Avaya is in talks to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TECK.B

Teck Corp.

$0.00

(0.00%)

13:34
04/25/19
04/25
13:34
04/25/19
13:34
Conference/Events
Teck Corp. management to meet with B.Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

CWT

California Water Service

$49.43

-0.57 (-1.14%)

13:32
04/25/19
04/25
13:32
04/25/19
13:32
Upgrade
California Water Service rating change  »

California Water Service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BHC

Bausch Health

$23.18

0.16 (0.70%)

13:30
04/25/19
04/25
13:30
04/25/19
13:30
Hot Stocks
Breaking Hot Stocks news story on Bausch Health »

Bausch Health trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 06

    May

  • 06

    May

AVYA

Avaya

$20.20

0.875 (4.53%)

13:28
04/25/19
04/25
13:28
04/25/19
13:28
Periodicals
Mitel offers to combine with Avaya in stock deal, WSJ says »

Mitel's bid values…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

CLVS

Clovis

$19.43

-0.4 (-2.02%)

13:25
04/25/19
04/25
13:25
04/25/19
13:25
Options
Clovis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 31

    May

AGN

Allergan

$140.66

0.98 (0.70%)

, TEVA

Teva

$15.07

0.065 (0.43%)

13:25
04/25/19
04/25
13:25
04/25/19
13:25
Conference/Events
Piper Jaffray specialty pharma analysts to hold analyst/industry conference call »

Specialty Pharmaceuticals…

AGN

Allergan

$140.66

0.98 (0.70%)

TEVA

Teva

$15.07

0.065 (0.43%)

ALDR

Alder Biopharmaceuticals

$13.95

0.29 (2.12%)

AMGN

Amgen

$179.82

1.56 (0.88%)

BHVN

Biohaven Pharmaceutical

$62.30

-0.855 (-1.35%)

LLY

Eli Lilly

$117.99

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

  • 21

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

ZM

Zoom Video

$64.49

1.175 (1.86%)

13:21
04/25/19
04/25
13:21
04/25/19
13:21
Hot Stocks
Zoom, Slack announce new partnership »

Zoom and Slack have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$23.18

0.16 (0.70%)

13:21
04/25/19
04/25
13:21
04/25/19
13:21
Hot Stocks
Bausch Health announces FDA approval of Duobrii for plaque psoriasis »

Bausch Health and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 06

    May

  • 06

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
04/25/19
04/25
13:17
04/25/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
04/25/19
04/25
13:16
04/25/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$382.62

7.3 (1.95%)

13:16
04/25/19
04/25
13:16
04/25/19
13:16
Recommendations
Boeing analyst commentary at Bernstein »

Bernstein says Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 29

    May

  • 05

    Jun

BA

Boeing

$382.62

7.3 (1.95%)

13:15
04/25/19
04/25
13:15
04/25/19
13:15
Periodicals
FAA targeting May 23 for meeting over 737 MAX changes, Aviation Week says »

The FAA is targeting May…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 29

    May

  • 05

    Jun

13:12
04/25/19
04/25
13:12
04/25/19
13:12
General news
7-Yr Note Auction Coupon Rate data reported »

7-Yr Note Auction Coupon…

13:12
04/25/19
04/25
13:12
04/25/19
13:12
General news
7-Yr Note Auction Total Amount data reported »

7-Yr Note Auction Total…

RSG

Republic Services

$79.29

-0.01 (-0.01%)

13:10
04/25/19
04/25
13:10
04/25/19
13:10
Options
Upside call buys in Republic Services ahead of earnings »

Upside call buys in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 05

    May

  • 17

    May

  • 05

    Jun

LUV

Southwest

$54.00

1.08 (2.04%)

13:06
04/25/19
04/25
13:06
04/25/19
13:06
Hot Stocks
Breaking Hot Stocks news story on Southwest »

Southwest continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 13

    Nov

LUV

Southwest

$54.00

1.08 (2.04%)

, BA

Boeing

$379.25

3.93 (1.05%)

13:06
04/25/19
04/25
13:06
04/25/19
13:06
Hot Stocks
Southwest expects FY19 capacity to increase 2%-3% y-o-y »

Says continues to have…

LUV

Southwest

$54.00

1.08 (2.04%)

BA

Boeing

$379.25

3.93 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

  • 15

    May

  • 21

    May

  • 29

    May

  • 05

    Jun

  • 13

    Nov

BUD

AB InBev

$86.38

-1.82 (-2.06%)

13:05
04/25/19
04/25
13:05
04/25/19
13:05
Options
Anheuser Busch call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 07

    May

13:05
04/25/19
04/25
13:05
04/25/19
13:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

APD

Air Products

$199.33

-0.17 (-0.09%)

, PKX

Posco

$55.45

-0.75 (-1.33%)

13:02
04/25/19
04/25
13:02
04/25/19
13:02
Hot Stocks
Air Products to supply Posco's cathode material manufacturing site in Gwangyang »

Air Products (APD)…

APD

Air Products

$199.33

-0.17 (-0.09%)

PKX

Posco

$55.45

-0.75 (-1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUV

Southwest

$54.18

1.26 (2.38%)

13:02
04/25/19
04/25
13:02
04/25/19
13:02
Hot Stocks
Southwest expects Q2 economic fuel costs $2.10-$2.20 per gallon »

Says continues to expect…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 13

    Nov

13:00
04/25/19
04/25
13:00
04/25/19
13:00
General news
Treasury $32 B 7-year auction preview: »

Treasury $32 B 7-year…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.